Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02730325 · ClinicalTrials.gov registry record · NA
To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients
A NA study, sponsored by Northwestern University.
- Terminated
- Registry status
- NA
- Development phase
- 10
- Enrollment target
NCT02730325 is a NA study that was terminated before completion, run by Northwestern University. The registered enrollment target is 10 participants.
The verdict
NCT02730325, a NA study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- NA
- Development phase
- 10 participants
- Enrollment target
Study Summary
The effects of serum-derived bovine immunoglobulin/protein isolate (SBI) will be evaluated and compared to matching placebo in two distinct patient populations: I. Hospitalized ulcerative colitis (UC) patients who tested positive for Clostridium difficile (C. difficile) at time of admission and are receiving vancomycin. II. Hospitalized UC patients who tested negative for C. difficile at time of admission.
Interventions
- OTHER Placebo
- OTHER Serum-derived bovine immunoglobulin/protein isolate (SBI)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2015-12 |
| Est. Completion | 2018-01-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02730325
The ClinicalTrials.gov registry entry for NCT02730325 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02730325 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02730325 about?
NCT02730325 is a clinical study titled "To Evaluate the Impact of SBI on C. Difficile in Hospitalized UC Patients". The effects of serum-derived bovine immunoglobulin/protein isolate (SBI) will be evaluated and compared to matching placebo in two distinct patient populations: I. Hospitalized ulcerative colitis (UC) patients who tested positive for Clostridium difficile (C. difficile) at time of admission and are...
What is the current status of trial NCT02730325?
This trial is currently terminated. It is a NA study. The enrollment target is 10 participants. The study started on 2015-12. Estimated completion is 2018-01-05.
What interventions are being tested in trial NCT02730325?
The interventions under investigation include: Placebo (OTHER), Serum-derived bovine immunoglobulin/protein isolate (SBI) (OTHER).
Who is sponsoring clinical trial NCT02730325?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.